Raffaele Colombo: Does CD30 expression predict the clinical benefit of BV for T- and B-cell lymphomas?
Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks Inc. shared a recent article by Wen Chen, et al, on X:
Authors: Wen Chen, Zhihong Zhang.
“Does CD30 expression predict the clinical benefit of brentuximab vedotin (BV) for T- and B-cell lymphomas?
- Efficacy across a wide range of CD30 expression levels, including low or undetectable CD30
- Activity not associated with CD30 expression levels.
Considering CD30 is its molecular target, theoretically, the level of CD30 expression should influence the efficacy of BV.
However, the published literature suggests otherwise, as evidenced by the results of various studies conducted in patients with T- and B-cell lymphomas.’
See also previous similar analysis and conclusions by Deepa Jagadeesh et al.”
Raffaele Colombo, a leading figure in the pharmaceutical industry is the Associate Director of Medicinal Chemistry at Zymeworks Inc.. His leadership and scientific acumen drive the discovery and optimization of novel drug candidates and advance the treatment landscape for various diseases.
More posts featuring Raffaele Colombo.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023